COEPTIS THERAPEUTICS HOLDING (COEP) Stock Price & Overview
NASDAQ:COEP • US19207A2078
Current stock price
The current stock price of COEP is 10.68 USD. Today COEP is down by -2.2%. In the past month the price decreased by -11.26%. In the past year, price increased by 13.86%.
COEP Key Statistics
- Market Cap
- 61.517M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
COEP Stock Performance
COEP Stock Chart
COEP Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to COEP. When comparing the yearly performance of all stocks, COEP is a bad performer in the overall market: 70.31% of all stocks are doing better.
COEP Earnings
COEP Forecast & Estimates
COEP Groups
Sector & Classification
COEP Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
COEP Ownership
COEP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.11 | 373.296B | ||
| AMGN | AMGEN INC | 15.28 | 190.378B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 169.926B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 115.264B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.78 | 80.002B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.53 | 43.521B | ||
| INSM | INSMED INC | N/A | 31.815B | ||
| BIIB | BIOGEN INC | 11.43 | 28.04B | ||
| NTRA | NATERA INC | N/A | 27.8B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.5 | 23.341B | ||
| MRNA | MODERNA INC | N/A | 21.157B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.471B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About COEP
Company Profile
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The company is headquartered in Wexford, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2020-12-17. The firm is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Company Info
IPO: 2020-12-17
COEPTIS THERAPEUTICS HOLDING
105 Bradford Road, Suite 420
Wexford PENNSYLVANIA US
Employees: 5
Phone: 17249346467
COEPTIS THERAPEUTICS HOLDING / COEP FAQ
What does COEPTIS THERAPEUTICS HOLDING do?
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The company is headquartered in Wexford, Pennsylvania and currently employs 5 full-time employees. The company went IPO on 2020-12-17. The firm is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
What is the stock price of COEPTIS THERAPEUTICS HOLDING today?
The current stock price of COEP is 10.68 USD. The price decreased by -2.2% in the last trading session.
Does COEP stock pay dividends?
COEP does not pay a dividend.
How is the ChartMill rating for COEPTIS THERAPEUTICS HOLDING?
COEP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the short interest for COEP stock?
The outstanding short interest for COEPTIS THERAPEUTICS HOLDING (COEP) is 8.73% of its float.